Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351965 | 0.91 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL2597485 | 0.91 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL30089783 | 0.91 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL55609 | 0.90 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL17335643 | 0.90 | MTNR1A (0.81) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL55491 | 0.89 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL81120 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL3919777 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL9731258 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL4217159 | 0.81 | MTNR1A (0.73) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197904-A1 | A PROCESS FOR THE SYNTHESIS OF ( R)-2-(( TERT-BUTOXYCARBONYL)AMINO)-3-(DIETHOXYPHOSPHORYL)PROPANOIC ACID OR OF PHOSPHONATE DERIVATIVES THEREOF | VIATRIS ASIA PACIFIC PTE LTD (SG) | 2025-06-19 | — | — | US | claimed |
| EP-4493565-A1 | A PROCESS FOR THE SYNTHESIS OF (R)-2-(( TERT-BUTOXYCARBONYL)AMINO)-3-(DIETHOXYPHOSPHORYL)PROPANOIC ACID OR OF PHOSPHONATE DERIVATIVES THEREOF | Viatris Asia Pacific Pte. Ltd. (SG) | 2025-01-22 | — | — | EP | claimed |
| CN-118871446-A | Synthesis method of (R) -2- ((tert-butoxycarbonyl) amino) -3- (diethoxyphosphoryl) propionic acid or phosphonate derivative thereof | 晖致亚太私人有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2023174810-A1 | A PROCESS FOR THE SYNTHESIS OF ( R)-2-(( TERT-BUTOXYCARBONYL)AMINO)-3-(DIETHOXYPHOSPHORYL)PROPANOIC ACID OR OF PHOSPHONATE DERIVATIVES THEREOF | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-21 | — | — | WO | claimed |
| WO-2005063240-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HYPERTENSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | claimed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | claimed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | claimed |
| JP-3169840-A | — | — | None | — | — | JP | disclosed |
| CN-122081247-A | Oncolytic vaccinia virus and recombinant viruses and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260109963-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING ADIPOSE TISSUE | OISIN BIOTECHNOLOGIES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| US-5151446-A | Neurological disorders or cardiovascular disorders | NORTHWESTERN UNIVERSITY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| JP-H03169840-A | SUBSTITUTED 2-AMIDOTETRALINS AS MELATONIN AGONISTS AND ANTAGONISTS | UNIV NORTHWESTERN | 1991-07-23 | — | — | JP | disclosed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109963-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING ADIPOSE TISSUE | FABP4, LPL, PNLIP | MTNR1A 3227/4885MTNR1B 2333/4885CYP1A2 4787/4885 |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | IRF3, IFNAR1, CXCL10 | MTNR1A 1806/4885MTNR1B 2283/4885CYP1A2 4154/4885 |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | REN, MTNR1A, MTNR1B | MTNR1A 2/4885MTNR1B 3/4885CYP1A2 914/4885 |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | CASP9, TP53, CASP2 | MTNR1A 4737/4885MTNR1B 4781/4885CYP1A2 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.